tiprankstipranks
BioCryst sees Q4 ORLADEYO net revenue $70.7M
The Fly

BioCryst sees Q4 ORLADEYO net revenue $70.7M

"In our second year on the market we more than doubled our first year ORLADEYO sales and are more than a quarter of the way towards $1 billion in peak sales. This continues to be an exceptional launch of an oral rare disease drug and we expect this success to continue creating real value for patients and for shareholders this year and for many years to come," said Jon Stonehouse, president and chief executive officer of BioCryst. Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2022 was $70.7 million. Preliminary, unaudited ORLADEYO net revenue for full year 2022 was $251.6 million.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BCRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles